Ventricular Pace Suppression Study (VpS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01053832
Recruitment Status : Completed
First Posted : January 21, 2010
Last Update Posted : October 25, 2011
Information provided by (Responsible Party):
Biotronik SE & Co. KG

January 19, 2010
January 21, 2010
October 25, 2011
January 2010
September 2011   (Final data collection date for primary outcome measure)
Reduction of right ventricular pacing with the help of the VpS algorithm in the EVIA/ ENTOVIS pacemakers. [ Time Frame: 6-8 months ]
Same as current
Complete list of historical versions of study NCT01053832 on Archive Site
A Complication free rate >95%, with respect to the VpS feature of the implanted pacemaker. [ Time Frame: 6-8 months ]
Same as current
Not Provided
Not Provided
Ventricular Pace Suppression Study
Ventricular Pace Suppression Study With the EVIA/ENTOVIS DR-T/DR Pacemaker
Investigation of the efficacy and safety of the Ventricular Pace Suppression (VpS) algorithm.
The aim of this study is to investigate the percentage of reduction of ventricular pacing using the VpS feature of the EVIA/ENTOVIS pacemaker in a controlled clinical investigation.
Not Applicable
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Supportive Care
Pacemaker Indication
Device: VpS algorithm in EVIA and ENTOVIS pacemakers
For one group of patients, the VpS algorithm will be activated and for the other group, the VpS algorithm will be deactivated until the cross-over, where these conditions will be switched.
  • Ventricular Pace Suppression- ON
    Intervention: Device: VpS algorithm in EVIA and ENTOVIS pacemakers
  • Ventricular Pace Suppression- OFF
    Intervention: Device: VpS algorithm in EVIA and ENTOVIS pacemakers
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
September 2011
September 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Paroxysmal AV block and/or Sinus Node Dysfunction
  • DDD(R)-ADI(R)-Mode (VpS Algorithm) applicability

Exclusion Criteria:

  • Permanent AV block III°
  • Permanent Atrial Fibrillation/ Flutter
  • Require mode other than DDD(R)-ADI(R) or DDD(R)
  • Have a life expectancy of less than six months
  • Expected to receive heart surgery within six months
  • Enrolled in another cardiac investigation
Sexes Eligible for Study: All
Child, Adult, Senior
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Biotronik SE & Co. KG
Biotronik SE & Co. KG
Not Provided
Principal Investigator: Hendrik Bonnemeier, Prof. Dr. Klinik für Kardiologie und Angiologie, UNIVERSITÄTSKLINIKUM Schleswig-Holstein, Campus Kiel
Biotronik SE & Co. KG
October 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP